文献速递消化道肿瘤放疗姑息放疗与转移瘤放疗物理与技术

不可切除局部复发直肠癌非手术管理的放疗剂量递增(STEP-UP):多中心前瞻性开放标签可行性研究方案

Radiotherapy dose escalation for the non-operative management of patients with unresectable locally recurrent rectal cancer (STEP-UP): Study protocol for a multicentre, prospective, open-label feasibility study.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-10-15

STEP-UP是一项多中心、前瞻性、单臂可行性研究,计划入组30例不可切除或无法手术的局部复发直肠癌患者(无远处转移或无需立即系统治疗的寡转移)。研究评估放疗剂量递增非手术管理的可行性,主要终点为≥3级急性放疗相关不良事件不超过7例(23%)。

要点

  • 不可切除LRRC非手术管理采用系统治疗联合放疗的双模式治疗,剂量递增的可行性与安全性尚未确立。
  • 既往放疗者可行时行SBRT再照射(5×9 Gy),或超分割放化疗再照射(50.4 Gy,1.2 Gy每日两次,同步卡培他滨)。
  • 未放疗者行同步整合加量放化疗(25×2.6 Gy,EQD2Gyα/β=5Gy为71 Gy,同步卡培他滨)。

核心结论

  • STEP-UP研究将确定不可切除局部复发直肠癌放疗剂量递增非手术管理的可行性,若可行且安全,可能提供一种有效的治疗强化策略。

研究设计与样本

  • 多中心、前瞻性、开放标签、单臂可行性研究,计划入组30例不可切除或无法手术的局部复发直肠癌患者。
  • 入组条件为无远处转移,或(寡)转移性疾病无需立即系统治疗。

主要发现

  • 主要终点为治疗方案可行性,定义为≥3级急性放疗相关不良事件(CTCAE 5.0版)发生于不超过7例患者(23%)。
  • 次要终点包括晚期不良事件、生活质量与症状控制,以及1年和3年无进展生存、无病生存和总生存。

关键数值与推荐

  • 既往放疗患者可行时行SBRT再照射(re-SBRT;5×9 Gy),或超分割放化疗再照射(50.4 Gy,1.2 Gy每日两次,同步卡培他滨)。
  • 未放疗患者行同步整合加量放化疗(25×2.6 Gy,EQD2Gyα/β=5Gy为71 Gy,同步卡培他滨)。
  • 主要终点阈值:≥3级急性放疗相关不良事件不超过7例(23%)。

临床怎么用

  • 为不可切除局部复发直肠癌的非手术管理提供剂量递增放疗的可行性及安全性数据,可能指导治疗强化策略以改善局部控制和症状负担。

局限性

  • 单臂可行性研究,样本量30例,不设对照组,可行性及安全性结果需后续研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Curative-intent management of locally recurrent rectal cancer (LRRC) generally comprises neoadjuvant therapy and surgery. In patients with unresectable LRRC, where surgical intervention is not feasible, management is limited to non-operative bimodality therapy with systemic therapy and radiotherapy. Evidence guiding the optimisation of non-operative management remains limited. In this context, the therapeutic goal is to achieve prolonged local control while minimising treatment-related adverse events and preserving quality of life. Radiotherapy dose escalation has been proposed as a potential strategy to achieve this balance. However, its feasibility and safety in the non-operative management of unresectable LRRC have not yet been established. As such, this study aims to evaluate the feasibility and safety of this radiotherapeutic approach, and to determine its impact on both symptom control and oncological outcomes. METHODS: This prospective, multicentre, single-arm feasibility study will enrol 30 patients with unresectable or inoperable LRRC without distant metastases, or with (oligo)metastatic disease not requiring immediate systemic therapy. Previously irradiated patients will undergo reirradiation with stereotactic body radiotherapy (re-SBRT; 5 × 9 Gy) when feasible, or, alternatively hyperfractionated chemo-reirradiation (50.4 Gy in 1.2 Gy twice-daily fractions with concurrent capecitabine). Radiotherapy-naïve patients will receive chemoradiotherapy with a simultaneous integrated boost (25 × 2.6 Gy, EQD2Gyα/β=5Gy of 71 Gy with concurrent capecitabine). [1] The primary endpoint is treatment regimen feasibility, defined as grade ≥ 3 acute radiotherapy-related adverse events (CTCAE version 5.0) occurring in no more than seven patients (23%). Secondary endpoints include late adverse events, quality of life and symptom control, and 1- and 3-year progression-free survival, disease-free survival, and overall survival. DISCUSSION: This protocol describes the STEP-UP study, which will determine the feasibility of radiotherapy dose escalation in unresectable LRRC. If feasible and safe, this approach could provide an effective treatment intensification strategy to improve local control and symptom burden in patients with unresectable LRRC, addressing a major unmet clinical need. TRIAL REGISTRATION: ClinicalTrials.gov: NCT07721181Overview of Medical-Scientific Research in the Netherlands (OMON) Registry: NL-011150.International Clinical Trial Registry Platform (ICTRP): NL-OMON61161.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Vande Kerckhove FEC, Beeftink JL, Tijssen RHN, et al. Radiotherapy dose escalation for the non-operative management of patients with unresectable locally recurrent rectal cancer (STEP-UP): Study protocol for a multicentre, prospective, open-label feasibility study. Clin Transl Radiat Oncol. 2026. PMID: 42927245. doi:10.1016/j.ctro.2026.101326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。